A Case of Polyserositis, Chylous Ascites and Hepatitis Induced by Immune Checkpoint Inhibitors.
| Autor: | Castelli M; Department of Oncology and Hematology, University of Milan and ASST Papa Giovanni XXIII, Bergamo, Italy., Betelli M; Internal Medicine Unit, ASST Papa Giovanni XXIII, Bergamo, Italy., Valenti A; Internal Medicine Unit, ASST Papa Giovanni XXIII, Bergamo, Italy., Merelli B; Oncology Unit, ASST Papa Giovanni XIII, Bergamo, Italy., Loglio A; Gastroenterology, Hepatology and Transplantation Unit, ASST Papa Giovanni XXIII, Bergamo, Italy., Viganò M; Gastroenterology, Hepatology and Transplantation Unit, ASST Papa Giovanni XXIII, Bergamo, Italy., Benetti A; Internal Medicine Unit, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | European journal of case reports in internal medicine [Eur J Case Rep Intern Med] 2024 May 31; Vol. 11 (7), pp. 004237. Date of Electronic Publication: 2024 May 31 (Print Publication: 2024). |
| DOI: | 10.12890/2024_004237 |
| Abstrakt: | We describe a rare case of polyserositis with chylous ascites following nivolumab therapy, highlighting the challenges in recognising and managing immune-related adverse events (irAEs) associated with immune checkpoint inhibitors (ICPIs). Induced polyserositis and chylous ascites are very rare and require immunosuppressive treatment, with a variable response of high-dose IV steroids. Learning Points: Oncological therapy with immune checkpoint inhibitors (ICPIs) is frequently associated with immune-related adverse events (irAEs) most involving cutaneous, gastrointestinal and pulmonary sites. Competing Interests: Conflicts of Interests: The Authors declare that there are no competing interests. (© EFIM 2024.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|